Dr. Megan E. Daly
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
10 reported clinical trials
24 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage I
2Lung Cancer
Stage III
Stage IV
Stage I
Affiliated Hospitals
Clinical Trials Megan E. Daly is currently running
Targeted Radionuclide Therapy
for Non-Small Cell Lung Cancer
This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
Recruiting1 award Phase 1
IL-2 + Radiotherapy + Pembrolizumab
for Refractory Cancers
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients \>18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 / PD-L1 checkpoint blockade therapy will be enrolled. Patients must have a candidate treatment lesion (subcutaneous, nodal, or visceral) accessible and safe for radiotherapy and serial intralesional injections as specified by the protocol. They must also have at least one target lesion (distinct from treatment lesion and outside of treatment lesion radiation field) evaluable for response by RECIST. This study will consist of a phase I dose escalation using a standard 3+3 design to determine safety and MTD of intralesional IL-2 which will be dose escalated in conjunction with standard fixed doses of RT and Pembrolizumab. At the MTD there will be a phase II dose expansion which will incorporate a simon-two stage design to assess efficacy and safety. Patients will receive pembrolizumab and intralesional IL-2 in combination with hypofractionated radiotherapy.
Recruiting1 award Phase 1 & 216 criteria
More about Megan E. Daly
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Megan E. Daly has experience with
- Pembrolizumab
- Atezolizumab
- Stereotactic Body Radiation Therapy
- Cisplatin
- Carboplatin
- Durvalumab
Breakdown of trials Megan E. Daly has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Megan E. Daly specialize in?
Megan E. Daly focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Megan E. Daly currently recruiting for clinical trials?
Yes, Megan E. Daly is currently recruiting for 7 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Megan E. Daly has studied deeply?
Yes, Megan E. Daly has studied treatments such as Pembrolizumab, Atezolizumab, Stereotactic Body Radiation Therapy.
What is the best way to schedule an appointment with Megan E. Daly?
Apply for one of the trials that Megan E. Daly is conducting.
What is the office address of Megan E. Daly?
The office of Megan E. Daly is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.